DDIT3 and diffuse large B-cell lymphoma: In another phase 3 study evaluating the efficacy of R-CHOP plus lenalidomide in previously untreated ABC DLBCL (ROBUST study), the NanoString Lymph2Cx GEP assay was applied to assign COO, demonstrating 15% failure in the test (29).